Cantor Fitzgerald Assumes Crinetics Pharmaceuticals at Overweight, Lowers Price Target of $50
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Charles Duncan has assumed Crinetics Pharmaceuticals (NASDAQ:CRNX) with an Overweight rating, but has lowered the price target to $50.
October 24, 2023 | 5:53 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald has given Crinetics Pharmaceuticals an Overweight rating, indicating a positive outlook, but has lowered the price target to $50.
The Overweight rating from Cantor Fitzgerald suggests that they expect Crinetics Pharmaceuticals' stock to outperform the market in the short term. However, the lowering of the price target could indicate a tempered expectation of the stock's potential upside. This could lead to increased buying interest in the short term, but also some caution due to the lowered price target.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100